Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo

Oncology Research

Volumn 19, Issue 7, 2011, Pages 349-363

  Davies, Kurtis D ^a   Humphries, Michael J ^a   Sullivan, Francis X ^a   Von Carlowitz, Ira ^a   Le Huerou, Yvan ^a   Mohr, Peter J ^a   Wang, Bin ^a   Blake, James F ^a   Lyon, Michael A ^a   Gunawardana, Indrani ^a   Chicarelli, Mark ^a   Wallace, Eli ^a   Gross, Stefan ^a  

^a ARRAY BIOPHARMA INC   (United States)

Author keywords

Cell cycle; Checkpoint; Checkpoint kinase 1 (Chk1); Chemopotentiation; Cyclin dependent kinase

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 A; DNA; PROTEIN SERINE THREONINE KINASE INHIBITOR; ROSCOVITINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN A549; CELL STRAIN HEL92.1.7; CELL STRAIN K 562; CELL STRAIN LNCAP; CELL STRAIN M059J; CELL STRAIN M059K; CELL STRAIN MCF7; CELL STRAIN MIAPACA 2; CELL STRAIN MOLM13; CELL STRAIN MV411; CELL STRAIN PANC 1; CELL STRAIN SET2; CELL STRAIN THP 1; CHROMATIN; CONTROLLED STUDY; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TUMOR XENOGRAFT;

EID: 80051887747     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X13079697132961     Document Type: Article

References (66)

1. Furnari, B.; Rhind, N.; Russell, P. Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 277: 1495-1497; 1997.
2. Sanchez, Y.; Wong, C.; Thoma, R. S.; et al. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497-1501; 1997.
3. Zhao, H.; Watkins, J. L.; Piwnica-Worms, H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc. Natl. Acad. Sci. USA 99:14795-14800; 2002.
4. Sorensen, C. S.; Syljuasen, R. G.; Falck, J.; et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3:247-258; 2003.
5. Lee, J.; Kumagai, A.; Dunphy, W. G. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol. Biol. Cell 12: 551-563; 2001.
6. Zachos, G.; Black, E. J.; Walker, M.; et al. Chk1 is required for spindle checkpoint function. Dev. Cell 12:247-260; 2007.
7. Sorensen, C. S.; Hansen, L. T.; Dziegielewski, J.; et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell. Biol. 7:195-201; 2005.
8. Bahassi, E. M.; Ovesen, J. L.; Riesenberg, A. L.; et al. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 27:3977-3985; 2008.
9. Huang, M.; Miao, Z. H.; Zhu, H.; et al. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol. Cancer Ther. 7:1440-1449; 2008.
10. Wang, X.; Kennedy, R. D.; Ray, K.; et al. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol. Cell. Biol. 27:3098-3108; 2007.
11. Guervilly, J. H.; Mace-Aime, G.; Rosselli, F. Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest defiin Fanconi anemia. Hum. Mol. Genet. 17:679-689; 2008.
12. Tse, A. N.; Rendahl, K. G.; Sheikh, T.; et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicdepenity of topoisomerase I poisons in vitro and in vivo. Clin. Cancer Res. 13:591-602; 2007.
13. Matthews, D. J.; Yakes, F. M.; Chen, J.; et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6: 104-110; 2007.
14. Blasina, A.; Hallin, J.; Chen, E.; et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol. Cancer Ther. 7:2394-2404; 2008.
15. Parsels, L. A.; Morgan, M. A.; Tanska, D. M.; et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol. Cancer Ther. 8: 45-54; 2009.
16. Zhang, C.; Yan, Z.; Painter, C. L.; et al. PF-00477736 mediates checkpoint kinase 1 signaling pathway and po-tentiates docetaxel-induced efficacy in xenografts. Clin. Cancer Res. 15:4630-4640; 2009.
17. Morgan, M. A.; Parsels, L. A.; Zhao, L.; et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70: 4972-4981; 2010.
18. Mitchell, J. B.; Choudhuri, R.; Fabre, K.; et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin. Cancer Res. 16:2076-2084; 2010.
19. Walton, M. I.; Eve, P. D.; Hayes, A.; et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol. Cancer Ther. 9:89-100; 2010.
20. Perez, R. P.; Lewis, L. D.; Beelen, A. P.; et al. Modulation of cell cycle progression in human tumors: a pharmacokiated netic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin. Cancer Res. 12:7079-7085; 2006.
21. Sampath, D.; Cortes, J.; Estrov, Z.; et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107:2517-2524; 2006.
22. Ashwell, S.; Janetka, J. W.; Zabludoff, S. Keeping checkpoint kinases in line: New selective inhibitors in clinical trials. Expert Opin. Investig. Drugs 17:1331-1340; 2008.
23. Dai, Y.; Grant, S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 16:376-383; 2010.
24. Liu, Q.; Guntuku, S.; Cui, X. S.; et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/ M DNA damage checkpoint. Genes. Dev. 14:1448-1459; 2000.
25. Takai, H.; Tominaga, K.; Motoyama, N.; et al. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev. 14:1439-1447; 2000.
26. Brown, E. J.; Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14:397-402; 2000.
27. Feijoo, C.; Hall-Jackson, C.; Wu, R.; et al. Activation of mammalian Chk1 during DNA replication arrest: A role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J. Cell Biol. 154:913-923; 2001.
28. Zachos, G.; Rainey, M. D.; Gillespie, D. A. Chk1-defiin cient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J. 22:713-723; 2003.
29. Zachos, G.; Rainey, M. D.; Gillespie, D. A. Chk1-dependent S-M checkpoint delay in vertebrate cells is linked to maintenance of viable replication structures. Mol. Cell. Biol. 25:563-574; 2005.
30. Zhang, Y. W.; Otterness, D. M.; Chiang, G. G.; et al. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol. Cell. 19:607-618; 2005.
31. Petermann, E.; Caldecott, K. W. Evidence that the ATR/ Chk1 pathway maintains normal replication fork progression during unperturbed S phase. Cell Cycle 5:2203-2209; 2006.
32. Despras, E.; Daboussi, F.; Hyrien, O.; Marheineke, K.; Kannouche, P. L. ATR/Chk1 pathway is essential for resumption of DNA synthesis and cell survival in UV-irradiated XP variant cells. Hum. Mol. Genet. 19:1690-1701; 2010.
33. Petermann, E.; Maya-Mendoza, A.; Zachos, G.; et al. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol. Cell. Biol. 26:3319-3326; 2006.
34. Lam, M. H.; Liu, Q.; Elledge, S. J.; Rosen, J. M. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6:45-59; 2004.
35. Syljuasen, R. G.; Sorensen, C. S.; Hansen, L. T.; et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell. Biol. 25:3553-3562; 2005.
36. Cho, S. H.; Toouli, C. D.; Fujii, G. H.; Crain, C.; Parry, D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 4:131-139; 2005.
37. Durkin, S. G.; Arlt, M. F.; Howlett, N. G.; Glover, T. W. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 25:4381-4388; 2006.
38. Jardim, M. J.; Wang, Q.; Furumai, R.; et al. Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. Mol. Biol. Cell. 20:3801-3809; 2009.
39. Chen, C. C.; Kennedy, R. D.; Sidi, S.; Look, A. T.; D'Andrea, A. CHK1 inhibition as a strategy for targeting Fanconi anemia (FA) DNA repair pathway deficient tumors. Mol. Cancer 8:24; 2009.
40. Beck, H.; Nahse, V.; Larsen, M. S.; et al. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J. Cell Biol. 188:629-638; 2010.
41. Gagou, M. E.; Zuazua-Villar, P.; Meuth, M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol. Biol. Cell 21: 739-752; 2010.
42. Niida, H.; Tsuge, S.; Katsuno, Y.; et al. Depletion of Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J. Biol. Chem. 280:39246-39252; 2005.
43. Rodriguez, R.; Meuth, M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol. Biol. Cell 17:402-412; 2006.
44. Sidi, S.; Sanda, T.; Kennedy, R. D.; et al. Chk1 suppresses replicaa caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133:864-877; 2008.
45. Myers, K.; Gagou, M. E.; Zuazua-Villar, P.; Rodriguez, R.; Meuth, M. ATR and Chk1 suppress a caspase-3-dependependent apoptotic response following DNA replication stress. PLoS Genet. 5:e1000324; 2009.
46. Rodriguez, R.; Gagou, M. E.; Meuth, M. Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofactor Cdc45. Cell. Death Differ. 15:889-898; 2008.
47. Morgan, M. A.; Parsels, L. A.; Parsels, J. D.; Lawrence, T. S.; Maybaum, J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 5:1983-1988; 2006.
48. Niida, H.; Katsuno, Y.; Banerjee, B.; Hande, M. P.; Nakanishi, M. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol. Cell. Biol. 27: 2572-2581; 2007.
49. Von Carlowitz, I.; Le Huerou, Y.; Humphries, M. J.; et al: Characterization of a novel, oral Chk1 inhibitor [abstract]. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009.
50. Clarke, C. A.; Clarke, P. R. DNA-dependent phosphorylaprogression tion of Chk1 and Claspin in a human cell-free system. Biochem. J. 388:705-712; 2005.
51. Janicke, R. U.; Sprengart, M. L.; Wati, M. R.; Porter, A. G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273:9357-9360; 1998.
52. Gabrielli, B. G.; De Souza, C. P.; Tonks, I. D.; et al. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J. Cell Sci. 109 (Pt. 5):1081-1093; 1996.
53. Loffler, H.; Rebacz, B.; Ho, A. D.; et al. Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle 5:2543-2547; 2006.
54. Leung-Pineda, V.; Ryan, C. E.; Piwnica-Worms, H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1- regulated protein phosphatase 2A circuit. Mol. Cell. Biol. 26:7529-7538; 2006.
55. Zhang, Y. W.; Brognard, J.; Coughlin, C.; et al. The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol. Cell 35:442-453; 2009.
56. Seiler, J. A.; Conti, C.; Syed, A.; Aladjem, M. I.; Pommier, Y. The intra-S-phase checkpoint affects both DNA replication initiation and elongation: Single-cell and -DNA fiber analyses. Mol. Cell. Biol. 27:5806-5818; 2007.
57. Gabrielli, B. G.; Roy, L. M.; Gautier, J.; Philippe, M.; Maller, J. L. A cdc2-related kinase oscillates in the cell cycle independently of cyclins G2/M and cdc2. J. Biol. Chem. 267:1969-1975; 1992.
58. Garrett, M. D.; Collins, I. Anticancer therapy with checkpoint inhibitors: What, where and when? Trends Pharmacol. Sci. 32(5):308-316; 2011.
59. Jallepalli, P. V.; Kelly, T. J. Cyclin-dependent kinase and initiation at eukaryotic origins: A replication switch? Curr. Opin. Cell Biol. 9:358-363; 1997.
60. Maya-Mendoza, A.; Petermann, E.; Gillespie, D. A.; Caldecott, K. W.; Jackson, D. A. Chk1 regulates the density of active replication origins during the vertebrate S phase. EMBO J. 26:2719-2731; 2007.
61. Petermann, E.; Woodcock, M.; Helleday, T. Chk1 promotes replication fork progression by controlling replication initiation. Proc. Natl. Acad. Sci. USA 107:16090-16095; 2010.
62. Byun, T. S.; Pacek, M.; Yee, M. C.; Walter, J. C.; Cimprich, K. A. Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes. Dev. 19:1040-1052; 2005.
63. Huang, Y.; Nakada, S.; Ishiko, T.; et al. Role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage. Mol. Cell. Biol. 19:2986-2997; 1999.
64. Levesque, A. A.; Fanous, A. A.; Poh, A.; Eastman, A. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Mol. Cancer Ther. 7:252-262; 2008.
65. Tse, A. N.; Schwartz, G. K. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 64:6635-6644; 2004.
66. Wang, Q.; Fan, S.; Eastman, A.; et al. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88:956-965; 1996.